Response Evaluation Criteria in Solid Tumors
"Response Evaluation Criteria in Solid Tumors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An internationally recognized set of published rules used for evaluation of cancer treatment that define when tumors found in cancer patients improve, worsen, or remain stable during treatment. These criteria are based specifically on the response of the tumor(s) to treatment, and not on the overall health status of the patient resulting from treatment.
| Descriptor ID |
D066066
|
| MeSH Number(s) |
E01.789.800.379 N04.761.559.590.800.569 N05.715.360.575.575.800.569
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Response Evaluation Criteria in Solid Tumors".
Below are MeSH descriptors whose meaning is more specific than "Response Evaluation Criteria in Solid Tumors".
This graph shows the total number of publications written about "Response Evaluation Criteria in Solid Tumors" by people in this website by year, and whether "Response Evaluation Criteria in Solid Tumors" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 0 | 1 | 1 |
| 2018 | 0 | 1 | 1 |
| 2019 | 1 | 1 | 2 |
| 2020 | 0 | 1 | 1 |
| 2021 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Response Evaluation Criteria in Solid Tumors" by people in Profiles.
-
Lenvatinib with etoposide plus ifosfamide in patients with refractory or relapsed osteosarcoma (ITCC-050): a multicentre, open-label, multicohort, phase 1/2 study. Lancet Oncol. 2021 09; 22(9):1312-1321.
-
Radiomics analysis for predicting pembrolizumab response in patients with advanced rare cancers. J Immunother Cancer. 2021 04; 9(4).
-
Response criteria for intraocular retinoblastoma: RB-RECIST. Pediatr Blood Cancer. 2021 05; 68(5):e28964.
-
Nivolumab in children and young adults with relapsed or refractory solid tumours or lymphoma (ADVL1412): a multicentre, open-label, single-arm, phase 1-2 trial. Lancet Oncol. 2020 04; 21(4):541-550.
-
Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria. AJR Am J Roentgenol. 2019 12; 213(6):1232-1239.
-
Multiple antigen-engineered DC vaccines with or without IFNa to promote antitumor immunity in melanoma. J Immunother Cancer. 2019 04 24; 7(1):113.
-
Anti-PD-1 antibody treatment for melanoma. Lancet Oncol. 2018 05; 19(5):e219.
-
Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol. 2017 Aug 01; 35(22):2580-2587.